Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC).
Year: 2010
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: J. Ang, T. A. Yap, P. Fong, C. P. Carden, D. S. Tan, J. Hanwell, J. Carmichael, J. S. De Bono, M. E. Gore, S. B. Kaye
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2227239144